Introduction {#s1}
============

Gilles de la Tourette syndrome (GTS) is neuropsychiatric disorder in which motor and vocal tics occur. They are usually accompanied by psychiatric comorbidities such as attention-deficit hyperactivity disorder (ADHD), obsessive--compulsive disorder (OCD), depression or self-injury. Segregation analysis in GTS-risk families suggests a complex, polygenic mode of inheritance involving various *loci* ([@B34]). Susceptibility genes associated with GTS include: Slit and Trk-like1 (*SLITRK1*), L-histidine decarboxylase (*HDC*), mitochondrial inner membrane protease subunit 2 (*IMMP2L*), neuroligin 4, X-linked (*NLGN4X*), contactin-associated protein 2 (*CNTNAP2*) (for details consult review by Paschou et. al ([@B45]), cadherin EGF LAG seven-pass G-type receptor 3 (*CELSR3*) ([@B59]; [@B57]), WW and C2 domain containing 1 (*WWC1)*, Nipped-B-like (*NIPBL*), fibronectin 1 (*FN1*) ([@B59]), arylacetamide deacetylase (*AADAC*) ([@B64]) and others.

Abnormal dopaminergic neurotransmission in the cortex and in the basal ganglia interacting with other neuronal pathways, including endocannabinoid system (ECS), seems to be crucial in GTS pathophysiology ([@B32]). Endocannabinoids mediate two pathways in the basal ganglia: neurons of the direct pathway expressing dynorphin and D1 dopamine receptor, as well as the indirect pathway neurons expressing enkephalin and D2 receptor ([@B53]; [@B35]). There are many further indications for an involvement of ECS in GTS ([@B51]; [@B29]; [@B16]; [@B40]; [@B42]; [@B43]; [@B17]; [@B4]; [@B35]; [@B55]; [@B22]; [@B26]). Some post-mortem studies support cannabinoid dysregulation in GTS, as decreased immunoreactivity with dynorphin A \[1--17\] has been detected in the striatal area of GTS patients ([@B16]). Furthermore, increased levels of dynorphin A \[1--8\] were found in the cerebrospinal fluid of GTS patients which correlated with OCD severity ([@B29]). The ECS involvement in GTS is also indicated by a neuroimaging study using single photon emission computed tomography (SPECT) with \[^123^I\]AM281 ([@B3]). The clinical efficacy of cannabis-based medicines (CBM) also supports the involvement of ECS ([@B43]; [@B44]). Additionally, a number of retrospective reports on self-medication with CBM ([@B19]; [@B42]; [@B4]; [@B22]) as well as case reports ([@B42]; [@B17]; [@B4]; [@B55]; [@B22]; [@B26]) suggest effectiveness of CBM in GTS.

The two main cannabinoid receptors are CB1 and CB2, cannabinoid receptors type 1 and 2. CB1 receptor is mostly present in the central nervous system, with a high density in basal ganglia ([@B46]), the brain region implicated in movement control, while CB2 receptor is mainly present in the immune system and in hematopoietic cells ([@B48]) where it modulates cytokine release ([@B54]). Variants of the *CNR1* gene encoding CB1 receptor have been associated with various psychiatric and neurological diseases ([@B14]; [@B15]; [@B8]; [@B10]; [@B47]; [@B61]) (see [**Table 1**](#T1){ref-type="table"}). [@B14] were the first to investigate polymorphisms in a coding exon of the *CNR1* gene finding the 1359(G/A) polymorphism in German GTS patients. Posteriorly they focused on *CNR1* variants in a larger group of GTS patients ([@B23]). However, they failed to find a correlation between those variants and GTS.

###### 

SNPs selected for the study.

  SNP         MAF (NFE)   Localization        Associated neuropsychiatric disorders
  ----------- ----------- ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  rs2023239   16%         intron              substance dependence ([@B18]; [@B13]), eating disorders ([@B38]), schizophrenia ([@B63]), impulsivity ([@B9]), depression ([@B21]), cyclic vomiting syndrome ([@B58])
  rs2180619   40%         promoter            anxiety ([@B28]), substance dependence ([@B6]), eating disorders ([@B39]), personality disorders ([@B61])
  rs806379    47%         intron              anxiety ([@B30]), substance dependence ([@B10]), schizophrenia ([@B63]), impulsivity ([@B5])
  rs1049353   27%         exon (synonymous)   substance dependence ([@B20]), eating disorders ([@B49]), schizophrenia ([@B54]), depression ([@B37]), multiple sclerosis ([@B56])

MAF, minor allele frequency, in gnomAD database; associated neuropsychiatric disorders based on SNPedia database.

SNP, single nucleotide polymorphism.

Despite that negative outcome we decided to revise the question of a possible role of CB1 receptor in GTS. We focused on the CB1 receptor as it is mainly expressed in the brain and mediates inhibition of dopaminergic, glutaminergic, and GABAergic neurotransmission in CNS ([@B18]). We hypothesized that ECS dysregulation in GTS could be related to some minor variants of the *CNR1* gene and therefore tested four such variants as possible risk factors of GTS in Polish GTS patients.

Material and Methods {#s2}
====================

Ethics Statement {#s2_1}
----------------

The study has been approved by the Ethics Committee of the Medical University of Warsaw (KB/2/2007, KB/53/A/2010, KB/63/A/2018) and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants aged ≥18 years signed an informed consent form prior to their inclusion in the study, and legal guardians gave a written consent on behalf of individuals under 18.

Study Participants {#s2_2}
------------------

The study group comprised 262 unrelated GTS patients aged 3--53 years (mean age: 18.3 ± 9.1 years; 204 males (77.9%), 126 (48.1%) adults defined as ≥18 years). The family history of tics was positive in 142 (54.8%) patients, and was unknown for three patient. The family history of OCD or obsessive--compulsive behavior (OCB) was available from 125 patients, and was positive for 37 (29.6%) patients. The mean age of tic onset was 6.9 ± 3.0 years. Two hundred and three (77.8%) patients had at least one of the following co-morbidities: OCD/OCB n = 127 (48.7%), ADHD n=90 (34.5%), non-OCD anxiety disorder n = 84 (32.2%), learning disorder n=64 (24.5%), depression n = 37 (14.2%), conduct disorder n=16 (6.1%), while 58 (22.2%) had none of the above. Yale Global Tic Severity Scale (YGTSS) was used to assess the severity of tics, but could only be performed for 127 (48.5%) patients. The control group comprised 279 unrelated, ethnically and gender matched individuals with no diagnosed mental, neurological or general disorders, aged 13--54 years (mean age: 22.5 ± 3.0 years; 200 males, (74.1%). The age of the controls was slightly higher (mean age of the two groups differed only by four years) as we wanted to be sure that the controls have passed the age of tic onset (the onset of GTS after 13 years is very rare).

The patients were evaluated for the clinical diagnosis of GTS and co-morbid mental disorders according to DSM-IV-TR, most of them before the DSM-5 criteria were published. Patients who fulfilled the DSM-5, but not DSM-IV-TR diagnostic criteria for GTS were excluded to ensure homogeneity of group. OCB was diagnosed if obsessions and compulsions were egosyntonic in contrast to egodystonic symptoms which characterized OCD. The diagnosis of co-morbid mental disorders was also made based on earlier psychiatric examinations that had been performed before the time of patients' evaluation. This included psychiatric disorders that were usually diagnosed in the childhood (e.g., attention deficit hyperactivity disorder or oppositional defiant disorder) and symptoms of which were not yet present in adult patients at the time of examination. All the patients were referred to a neurologist experienced in tic disorders and were personally interviewed by an author of the study (PJ). The study was designed as a one-time registration study and no new clinical data obtained on follow-up visits have been included in the analysis.

Genetic Analysis and Selection of SNPs {#s2_3}
--------------------------------------

DNA samples were collected between 2007 and 2018. Genomic DNA was extracted either from peripheral blood leukocytes using a standard salting-out procedure ([@B36]) or from buccal cells collected with Oragene OG-500 DNA collection kit and using Prep IT L2P purification kit (DNA Genotek Inc., Ottawa, Ontario, Canada). The latter method was used with young patients that were unable or unwilling to comply with blood collections. DNA samples obtained with both methods were of same quality and applicability. Genotyping of selected SNPs was performed using TaqMan SNP genotyping assays (Life Technologies, Carlsbad, California, USA) on a StepOne Plus Real-Time PCR system (Life Technologies) ([@B23]).

*The* rs2023239, rs2180619, rs806379, and rs1049353 *CNR1* polymorphisms were chosen on the basis of their minor allele frequency (MAF) estimated above 15% in both general and Polish populations, and their well-documented association with various neurological and psychiatric disorders ([**Table 1**](#T1){ref-type="table"}). As indicated by data from the Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database (GnomAD) rs1049353 is the only known polymorphism in the coding sequence of the *CNR1* gene with a MAF above 1%; it is synonymous. All other published variants in the coding sequence are private withfrequency of at most hundreds per 276,000 alleles (MAF below 0.4%) and therefore were not selected for the study. Also in our in-house database of whole exome/genome sequencing results for \>200 Polish patients not affected by GTS, the rs1049353 variant is the only one located in the coding sequence of *CNR1*. Thus, except for rs1049353, the selected SNPs are located in non-coding sequences. For clarity we note that rs1049353 is different from the 1359(G/A) polymorphism studied by Gadzicki et al. ([@B31]).

Statistical Analysis {#s2_4}
--------------------

Chi-square test was used for both allelic and genotypic association studies. Association of genotypes with age of tic onset and YGTSS was analyzed with Kruskal-Wallis test. Multivariate logistic regression model was used to find independent predictors of GTS risk. The study sample size was sufficient to detect with 80% probability the true effect size measured as odds ratio (OR) between 1.62 and 1.97 for positive association or between 0.39 and 0.61 for negative association (depending on the actual MAF which ranged from 0.11 to 0.47) for the differences in allele frequencies of the four polymorphisms between the GTS and the control group. Statistica 13 program was used for statistical calculations. The significance level was set at p \< 0.05, and Bonferroni-corrected significance criterion was used where indicated in the text.

Results {#s3}
=======

The genotyping success rate was 100% and the consensus rate (on the basis of 10% duplicates) was 100% for DNA isolated from both leukocytes and buccal cells. The quality of genotyping was the same regardless of the biological source and method used for DNA isolation. The genotype frequencies of all four SNPs were in accordance with the Hardy--Weinberg equilibrium in the control group (p\>0.9 for rs806379, p\>0.3 for rs2023239, p\>0.6 for rs2180619 and p\>0.6 for rs1049353). In the patient group the genotype frequencies of three SNPs were in accordance with the Hardy--Weinberg equilibrium (p\>0.2 for rs2023239, p\>0.1 for rs2180619 and p\>0.2 for rs1049353) while the distribution of the rs806379 genotype deviated slightly from the Hardy-Weinberg equilibrium (p=0.047) due to a deficit of heterozygotes.

A significant association with the GTS was found for the rs2023239 variant. The MAF of *CNR1* rs2023239 was significantly higher in GTS patients compared to control group. When the TT genotype was used as a reference, genotypes CC+CT (dominant model, p = 0.001) and CT alone (p = 0.0009) were significantly associated with a higher risk of GTS. This association remained significant after Bonferroni correction for multiple tests (Bonferroni-corrected significance level for four SNPs and six genetic models is 0.05/(4\*6)=0.002). There were no statistically significant associations between the rs2180619, rs806379 rs1049353 variants and the GTS ([**Table 2**](#T2){ref-type="table"}). Multivariate logistic regression analysis adjusted for gender and age showed that the presence of *CNR1* rs2023239 allele C (genotypes CC+CT, dominant model) is an independent factor associated with a higher risk of GTS ([**Table 3**](#T3){ref-type="table"}).

###### 

Genotype and allele distribution of the selected SNPs in patients with Gilles de la Tourette syndrome and controls.

  *CNR1* rs2023239   Comparison ^a^   OR ^b^   95%CI         p ^c^                                                 
  ------------------ ---------------- -------- ------------- ------- ------- ------------- ------- ------- ------- -------
                     TT               CT       CC            T       C       CC vs CT+TT   1.066   0.305   3.726   0.920
  Controls n         222              52       5             496     62      CC vs TT      1.261   0.360   4.426   0.716
  \%                 79.6             18.6     1.8           88.9    11.1    C vs T        1.681   1.188   2.380   0.003
  GTS n              176              81       5             433     91      CT vs TT      1.965   1.316   2.933   0.001
  \%                 67.2             30.9     1.9           82.6    17.4    CC vs CT      0.642   0.177   2.327   0.497
  *CNR1* rs2180619   Comparison ^a^   OR ^b^   95%CI         p ^c^                                                 
  Group              Genotype         Allele   GG+AG vs AA   1.281   0.903   1.818         0.164                   
                     AA               AG       GG            A       G       GG vs AG+AA   0.866   0.531   1.412   0.563
  Controls n         112              126      41            350     208     GG vs AA      1.032   0.606   1.758   0.909
  \%                 40.1             45.2     14.7          62.7    37.3    G vs A        1.090   0.853   1.393   0.491
  GTS n              90               138      34            318     206     AG vs AA      1.363   0.944   1.969   0.099
  \%                 34.4             52.7     13.0          60.7    39.3    GG vs AG      0.757   0.453   1.267   0.289
  *CNR1* rs806379    Comparison ^a^   OR ^b^   95%CI         p ^c^                                                 
  Group              Genotype         Allele   TT+AT vs AA   0.837   0.579   1.210         0.344                   
                     AA               AT       TT            A       T       TT vs AT+AA   1.204   0.807   1.797   0.362
  Controls n         78               141      60            297     261     TT vs AA      1.018   0.638   1.625   0.940
  \%                 28.0             50.5     21.5          53.2    46.8    T vs A        0.992   0.781   1.259   0.945
  GTS                83               114      65            280     244     AT vs AA      0.760   0.512   1.129   0.173
  n                                                                                                                
  \%                 31.7             43.5     24.8          53.4    46.6    TT vs AT      1.340   0.873   2.058   0.181
  *CNR1* rs1049353   Comparison ^a^   OR ^b^   95%CI         p ^c^                                                 
  Group              Genotype         Allele   TT+CT vs CC   0.876   0.622   1.232         0.445                   
                     CC               CT       TT            C       T       TT vs CT+CC   0.626   0.269   1.456   0.273
  Controls n         156              108      15            420     138     TT vs CC      0.604   0.257   1.421   0.244
  \%                 55.9             38.7     5.4           75.1    24.9    T vs C        0.865   0.653   1.147   0.314
  GTS                                                                                                              
  n                  155              98       9             408     116     CT vs CC      0.913   0.642   1.299   0.613
  \%                 59.2             37.4     3.4           78.0    22.0    TT vs CT      0.661   0.277   1.579   0.349

^a^Comparison of genotype or allele frequencies between the GTS and control groups, ^b^ OR for the genotype or allele frequencies compared between GTS patients and controls, ^c^ Chi^2^ test

###### 

Multivariate logistic regression analysis of independent factors associated with presence of GTS as dependent variable (GTS patients vs controls).

  Independent variables            OR      95%CI   p       
  -------------------------------- ------- ------- ------- -----------
  Gender (male vs female)          0.922   0.601   1.414   0.710
  Age (per 1 year)                 0.906   0.879   0.934   \<0.00001
  *CNR1* rs2023239 (CC+CT vs TT)   1.725   1.146   2.598   0.009

Genotypic and allelic association analysis of all four *CNR1* polymorphisms with most common co-morbid disorders in patients with GTS are shown in [**Table 4**](#T4){ref-type="table"}. The only significant association was found for rs806379. The minor allele T of this SNP was more frequent in GTS patients with ADHD than in the patients without ADHD (OR 1.45, 95% CI: 1.01--2.08, p=0.045). No associations were found between the *CNR1* genotype and age of tic onset (p\>0.4), total YGTSS or YGTSS Total Tic Score (p\>0.15), family history of tics (p\>0.15) or family history of OCB/OCD (p\>0.2).

###### 

Genotypic and allelic association analysis of studied *CNR1* variants with most common co-morbid disorders in patients with Gilles de la Tourette syndrome.

  Co-morbid disorder   *CNR1* rs2023239   Comparison ^a^   OR ^b^        95%CI   p ^c^                                          
  -------------------- ------------------ ---------------- ------------- ------- ------- ------------- ------- ------- -------- -------
  ADHD                 Genotype           Allele           CC+CT vs TT   1.289   0.753   2.206         0.354                    
                       TT                 CT               CC            T       C       CC vs CT+TT   0.469   0.052   4.261    0.491
  Absent, n            118                49               4             285     57      CC vs TT      0.518   0.057   4.737    0.553
  \%                   69.0               28.7             2.3           83.3    16.7    C vs T        1.164   0.728   1.862    0.525
  Present, n           57                 32               1             146     34      CT vs TT      1.352   0.783   2.335    0.279
  \%                   63.3               35.6             1.1           81.1    18.9    CC vs CT      0.383   0.041   3.582    0.384
  OCD/OCB              Genotype           Allele           CC+CT vs TT   0.619   0.367   1.044         0.071                    
                       TT                 CT               CC            T       C       CC vs CT+TT   1.597   0.262   9.717    0.608
  Absent, n            83                 49               2             215     53      CC vs TT      1.353   0.221   8.299    0.743
  \%                   61.9               36.6             1.5           80.2    19.8    C vs T        0.714   0.452   1.128    0.147
  Present, n           92                 32               3             216     38      CT vs TT      0.589   0.345   1.006    0.052
  \%                   72.4               25.2             2.4           85.0    15.0    CC vs CT      2.297   0.363   14.518   0.365
  Anxiety              Genotype           Allele           CC+CT vs TT   0.947   0.544   1.649         0.848                    
                       TT                 CT               CC            T       C       CC vs CT+TT   3.241   0.531   19.772   0.179
  Absent, n            118                57               2             293     61      CC vs TT      3.105   0.505   19.106   0.200
  \%                   66.7               32.2             1.1           82.8    17.2    C vs T        1.044   0.645   1.690    0.860
  Present, n           57                 24               3             138     30      CT vs TT      0.872   0.492   1.545    0.638
  \%                   67.9               28.6             3.6           82.1    17.9    CC vs CT      3.563   0.559   22.695   0.156
  Depression           Genotype           Allele           CC+CT vs TT   0.841   0.394   1.793         0.653                    
                       TT                 CT               CC            T       C       CC vs CT+TT   1.528   0.166   14.059   0.706
  Absent, n            149                71               4             369     79      CC vs TT      1.433   0.154   13.331   0.751
  \%                   66.5               31.7             1.8           82.4    17.6    C vs T        0.904   0.465   1.756    0.766
  Present, n           26                 10               1             62      12      CT vs TT      0.807   0.369   1.765    0.591
  \%                   70.3               27.0             2.7           83.8    16.2    CC vs CT      1.775   0.180   17.513   0.619
  ADHD                 Genotype           Allele           GG+AG vs AA   0.864   0.506   1.473         0.590                    
                       AA                 AG               GG            A       G       GG vs AG+AA   0.544   0.235   1.257    0.150
  Absent, n            57                 88               26            202     140     GG vs AA      0.531   0.216   1.308    0.165
  \%                   33.3               51.5             15.2          59.1    40.9    G vs A        0.816   0.562   1.184    0.283
  Present, n           33                 49               8             115     65      AG vs AA      0.962   0.553   1.672    0.890
  \%                   36.7               54.4             8.9           63.9    36.1    GG vs AG      0.553   0.232   1.314    0.175
  OCD/OCB              Genotype           Allele           GG+AG vs AA   0.986   0.592   1.643         0.957                    
                       AA                 AG               GG            A       G       GG vs AG+AA   0.531   0.251   1.125    0.095
  Absent, n            46                 66               22            158     110     GG vs AA      0.570   0.252   1.289    0.175
  \%                   34.3               49.3             16.4          59.0    41.0    G vs A        0.858   0.604   1.220    0.394
  Present, n           44                 71               12            159     95      AG vs AA      1.125   0.661   1.915    0.665
  \%                   34.7               55.9             9.5           62.6    37.4    GG vs AG      0.507   0.233   1.105    0.084
  Anxiety              Genotype           Allele           GG+AG vs AA   0.855   0.497   1.470         0.571                    
                       AA                 AG               GG            A       G       GG vs AG+AA   0.730   0.324   1.641    0.444
  Absent, n            59                 93               25            211     143     GG vs AA      0.685   0.285   1.647    0.397
  \%                   33.3               52.5             14.1          59.%    40.4    G vs A        0.863   0.591   1.260    0.445
  Present, n           31                 44               9             106     62      AG vs AA      0.900   0.512   1.582    0.715
  \%                   36.9               52.4             10.7          63.%    36.9    GG vs AG      0.761   0.328   1.766    0.524
  Depression           Genotype           Allele           GG+AG vs AA   0.844   0.411   1.733         0.643                    
                       AA                 AG               GG            A       G       GG vs AG+AA   0.784   0.259   2.370    0.666
  Absent, n            76                 118              30            270     178     GG vs AA      0.724   0.220   2.376    0.593
  \%                   33.9               52.7             13.4          60.3    39.7    G vs A        0.871   0.523   1.451    0.596
  Present, n           14                 19               4             47      27      AG vs AA      0.874   0.414   1.847    0.724
  \%                   37.8               51.4             10.8          63.5    36.5    GG vs AG      0.828   0.262   2.616    0.748
  Depression           Genotype           Allele           TT+CT vs CC   0.997   0.491   2.024         0.992                    
                       CC                 CT               TT            C       T       TT vs CT+CC   0.000   --      --       0.243
  Absent, n            133                83               8             349     99      TT vs CC      0.000   --      --       0.252
  \%                   59.4               37.1             3.6           77.9    22.1    T vs C        0.896   0.487   1.648    0.724
  Present, n           22                 15               0             59      15      CT vs CC      1.093   0.536   2.225    0.807
  \%                   59.5               40.5             0.0           79.7    20.3    TT vs CT      0.000   --      --       0.232
  Anxiety              Genotype           Allele           TT+CT vs CC   1.232   0.728   2.085         0.436                    
                       CC                 CT               TT            C       T       TT vs CT+CC   1.274   0.297   5.462    0.744
  Absent, n            108                64               5             280     74      TT vs CC      1.379   0.316   6.007    0.668
  \%                   61.0               36.2             2.8           79.1    20.9    T vs C        1.182   0.763   1.832    0.453
  Present, n           47                 34               3             128     40      CT vs CC      1.221   0.712   2.092    0.468
  \%                   56.0               40.5             3.6           76.2    23.8    TT vs CT      1.129   0.254   5.014    0.873
  OCD/OCB              Genotype           Allele           TT+CT vs CC   0.796   0.485   1.307         0.367                    
                       CC                 CT               TT            C       T       TT vs CT+CC   0.624   0.146   2.667    0.521
  Absent, n            76                 53               5             205     63      TT vs CC      0.577   0.133   2.499    0.458
  \%                   56.7               39.6             3.7           76.5    23.5    T vs C        0.817   0.539   1.241    0.343
  Present, n           79                 45               3             203     51      CT vs CC      0.817   0.492   1.356    0.434
  \%                   62.2               35.4             2.4           79.9    20.1    TT vs CT      0.707   0.160   3.121    0.646
  ADHD                 Genotype           Allele           TT+CT vs CC   1.107   0.659   1.859         0.701                    
                       CC                 CT               TT            C       T       TT vs CT+CC   1.942   0.474   7.955    0.348
  Absent, n            103                64               4             270     72      TT vs CC      1.981   0.476   8.239    0.339
  \%                   60.2               37.4             2.3           79.0    21.1    T vs C        1.141   0.741   1.759    0.549
  Present, n           52                 34               4             138     42      CT vs CC      1.052   0.617   1.793    0.851
  \%                   57.8               37.8             4.4           76.7    23.3    TT vs CT      1.882   0.443   8.000    0.385
  Anxiety              Genotype           Allele           TT+AT vs AA   1.445   0.811   2.575         0.210                    
                       AA                 AT               TT            A       T       TT vs AT+AA   1.106   0.610   2.006    0.741
  Absent, n            60                 74               43            194     160     TT vs AA      1.395   0.687   2.835    0.356
  \%                   33.9               41.8             24.3          54.8    45.2    T vs A        1.213   0.839   1.752    0.304
  Present, n           22                 40               22            84      84      AT vs AA      1.474   0.792   2.745    0.220
  \%                   26.2               47.6             26.2          50.0    50.0    TT vs AT      0.947   0.498   1.798    0.867
  Depression           Genotype           Allele           TT+AT vs AA   0.716   0.348   1.475         0.364                    
                       AA                 AT               TT            A       T       TT vs AT+AA   0.668   0.278   1.603    0.363
  Absent, n            68                 98               68            234     214     TT vs AA      0.586   0.222   1.550    0.278
  \%                   30.4               43.8             30.4          52.2    47.8    T vs A        0.746   0.452   1.229    0.248
  Present, n           14                 16               14            44      30      AT vs AA      0.793   0.363   1.732    0.560
  \%                   37.8               43.2             37.8          59.5    40.5    TT vs AT      0.739   0.287   1.903    0.530
  OCD/OCB              Genotype           Allele           TT+AT vs AA   0.925   0.548   1.560         0.769                    
                       AA                 AT               TT            A       T       TT vs AT+AA   1.031   0.588   1.807    0.915
  Absent, n            41                 60               33            142     126     TT vs AA      0.970   0.506   1.859    0.926
  \%                   30.6               44.8             24.6          53.0    47.0    T vs A        0.978   0.693   1.379    0.898
  Present, n           41                 54               32            136     118     AT vs AA      0.900   0.510   1.588    0.716
  \%                   32.3               42.5             25.2          53.5    46.5    TT vs AT      1.077   0.586   1.982    0.810
  ADHD                 Genotype           Allele           TT+AT vs AA   1.822   1.020   3.255         0.041                    
                       AA                 AT               TT            A       T       TT vs AT+AA   1.375   0.771   2.454    0.280
  Absent, n            61                 71               39            193     149     TT vs AA      1.937   0.960   3.906    0.063
  \%                   35.7               41.5             22.8          56.4    43.6    T vs A        1.448   1.008   2.080    0.045
  Present, n           21                 43               26            85      95      AT vs AA      1.759   0.943   3.283    0.075
  \%                   23.3               47.8             28.9          47.2    52.8    TT vs AT      1.101   0.590   2.055    0.763

^a^Comparison of genotype or allele frequencies between the GTS patients with and without particular co-morbid disorder, ^b^ OR for the genotype or allele frequencies compared between GTS patients with and without particular co-morbid disorder, ^c^ Chi^2^ test

Discussion {#s4}
==========

So far the only comprehensive study investigating genetic variation in the *CNR1* gene in GTS ([@B23]) was aimed to localize pathogenic mutations in *CNR1* and failed to show differences with healthy controls. Our study is the first to examine common SNP variants of *CNR1* gene in a group of GTS patients. A significant association was found both in the allelic and genotypic analysis between the risk of GTS and the rs2023239 polymorphism. Multivariate analysis proved that CC+CT genotypes are gender-independent factors associated with a higher GTS risk. Our study shows that GTS is associated with rs2023239 polymorphism along with various others neuropsychiatric disorders, such as the cannabis dependence ([@B2]), eating disorders ([@B63]), schizophrenia ([@B60]), impulsivity ([@B25]), depression ([@B47]), and migraine ([@B27]). We can only speculate on the molecular mechanism underlying the role of this variant in the pathogenesis of GTS. rs2023239 allele C was found to be associated with increased CB1 receptor density ([@B24]) which could modulate neurotransmission. It is unlikely that this intronic variant directly affects the splicing, as it is too distant the adjacent exon (122bp). Human Splicing Finder predicts that the minor allele C does not create any new potential splice sites or new potential branch points compared to the common T allele. Additionally, this variant could affect gene expression either directly or through a linkage to functional variant(s) located in regulatory regions.

Our earlier association studies in Polish patients with GTS have revealed a relationship between some SNPs of *BTBD9, ADORA1* and *ADORA2A* genes and co-morbid psychiatric disorders ([@B41]; [@B33]). Therefore, we hypothesized that *CNR1* variants could also contribute to the disease complexity predisposing the patients to psychiatric comorbidities as all the *CNR1* polymorphisms studied here had been found to be associated with various psychiatric disorders ([**Table 1**](#T1){ref-type="table"}). However, both genotypic and allelic association analyses of all the *CNR1*variants examined, including rs2023239 associated with a higher risk of GTS, failed to demonstrate a significant association with any psychiatric co-morbidity. The only statistically significant association found, that of co-morbid ADHD with rs806379, should probably be regarded as a false positive because of its marginal significance (0.05\>p\>0.04) in multiple statistical tests performed (4 SNPs x 4 disorders x 6 models).

A number of open as well as randomized controlled studies and case reports support the premise that the use of CBM improves not only tics, but also ADHD ([@B1]), OCB/OCD ([@B17]; [@B7]), depression ([@B62]) and anxiety ([@B22]). Our study does not confirm that this beneficial effect of CMB on co-morbid disorders in GTS could be related to *CNR1* SNPs as we did not find any association of the *CNR1* variants with co-morbidity. Additionally, we did not find any correlation of *CNR1* variants with any clinical data, such as age of tic onset, tic severity measured with YGTSS or familial history of tics and OCD/OCB. It can therefore be speculated that while rs2023239 contributes to the pathogenesis of tics *per se*, other genetic and environmental factors contribute to further clinical features of GTS.

The present results on the *CNR1* variants could also be interpreted in relation to an earlier SNP study by our group, in which we found association of *ADORA1* and *ADORA2A* variants with a higher risk of GTS ([@B41]). In this context we note that abnormality of the dopaminergic system has been confirmed to be one of the primary causes of GTS ([@B52]; [@B50]; [@B11]; [@B12]; [@B13]), both adenosine and endocannabinoids act as modulators of dopamine neurotransmission in the striatum ([@B38]) and it has been suggested that CB1 receptors form heteromers with dopamine D2 and adenosine A2A receptors ([@B9]). Although we do not know the functional significance of the minor variant of rs2023239 in GTS, we put forward the hypothesis that it could be related to faulty cannabinoid transmission due to lower expression of the CB1 receptor or reduced receptor's affinity for the endocannabinoid ligand. This, in turn, could lead to reduction of adenosinergic signaling and over-activity of dopaminergic transmission, and finally aggravate tics. Another possible mechanism is a direct enhancement of dopaminergic transmission as a consequence of limited endocannabinoid activity, without an involvement of adenosine signaling.

In conclusion, the obtained results indicate that the C allele of the rs2023239 polymorphism of *CNR1* gene is a risk factor of GTS in the Polish population, associated with the occurrence of tics, but not with the co-existing psychiatric symptoms. The results also support the hypothesis of an ECS involvement in the pathogenesis of GTS. Nevertheless, our finding is preliminary and needs to be replicated in an independent cohort. Further research is needed to determine functional significance of the variant.

Limitations {#s5}
===========

The following limitations of the study have to be addressed: 1) the analyzed variants can be in linkage disequilibrium with true risk conferring variants located outside analyzed regions; 2) the study group was relatively small; 3) the patients were evaluated for co-morbid disorders only once (one-time registration) and it cannot be excluded that psychiatric disorders could develop over time and additionally it was impossible to measure the YGTSS in all patients; there is a possibility of false negative results in rs2180619, rs806379, and rs1049353 CNR1 polymorphisms; 4) some clinical data, especially on adult patients, were subject to a recall bias, ; 5) we have not included the comparison with the variants previously associated with GTS and this should be taken into consideration in the future studies; and 6) our finding needs to be replicated using study groups from different populations.

Data Availability Statement {#s6}
===========================

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher. These are also included in [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

Ethics Statement {#s7}
================

The study has been approved by the Ethics Committee of the Medical University of Warsaw (KB/2/2007, KB/53/A/2010, KB/63/A/2018) and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants aged ≥18 years signed an informed consent form prior to their inclusion in the study, and legal guardians gave a written consent on behalf of individuals under 18.

Author Contributions {#s8}
====================

Research project: Conception (PJ), Organization (PJ, CŻ), Execution (JF), Creation of electronic database (TD, NS, PJ), Clinical examination: (PJ), Manuscript Preparation: Writing of the first draft (NS, PJ, JF, KS), Review and Critique (CŻ, PJ, KS, JF, NS, TD).

Funding {#s9}
=======

This study was kindly supported by a grant provided by Medical University of Warsaw (1WC/NM1/17) and by a grant funded by National Science Center (UMO-2016/23/B/NZ2/03030).

Conflict of Interest {#s10}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We thank all patients for participation in this study.

Supplementary Material {#s11}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2020.00125/full#supplementary-material>

###### 

The raw data used for analysis in this study.

###### 

Click here for additional data file.

[^1]: Edited by: Fabricio A. Pamplona, Entourage Phytolab, Brazil

[^2]: Reviewed by: Stefan Unterecker, University Hospital Würzburg, Germany; Geison Souza Izídio, Federal University of Santa Catarina, Brazil; Daniel Luís, HeartGenetics, Genetics and Biotechnology, S.A., Portugal

[^3]: †These authors have contributed equally to this work

[^4]: This article was submitted to Behavioral and Psychiatric Genetics, a section of the journal Frontiers in Genetics
